Human CD38 Protein
Catalog No: CD38-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human CD38 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Val43-Ile300 (UniProt accession: P28907-1).
Product Details
- Molecular Aliases
- ADPRC 1; T10; CD38; ADP-ribosyl cyclase 1; cADPr hydrolase 1; CD38 molecule; EC 2.4.99.20; EC 3.2.2.6;ADPRC1; EC2.4.99.20; EC3.2.2.6
- Protein Length
- Val43-Ile300
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 56.6 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human CD38 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CD38 is greater than 95% as determined by SEC-HPLC.
Immobilized Human CD38, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-CD38 Antibody, hFc Tag with the EC50 of 19.6ng/ml determined by ELISA (QC Test).
Background
CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic origin. CD38 is a transmembrane glycoprotein with ectoenzymatic activity, and also functions as a receptor and adhesion molecule. Altogether, this has triggered the development of several CD38 antibodies including daratumumab (fully human), isatuximab (chimeric), and MOR202 (fully human).
References
- van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8. PMID: 29118010.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.